143 related articles for article (PubMed ID: 30809471)
21. Development of a Quantitative Immunoassay for Tear Lacritin Proteoforms.
Justis BM; Coburn CE; Tyler EM; Showalter RS; Dissler BJ; Li M; McNamara NA; Laurie GW; McKown RL
Transl Vis Sci Technol; 2020 Aug; 9(9):13. PubMed ID: 32879769
[TBL] [Abstract][Full Text] [Related]
22. An NGF mimetic, MIM-D3, stimulates conjunctival cell glycoconjugate secretion and demonstrates therapeutic efficacy in a rat model of dry eye.
Jain P; Li R; Lama T; Saragovi HU; Cumberlidge G; Meerovitch K
Exp Eye Res; 2011 Oct; 93(4):503-12. PubMed ID: 21726552
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic efficacy of fibroblast growth factor 10 in a rabbit model of dry eye.
Zheng W; Ma M; Du E; Zhang Z; Jiang K; Gu Q; Ke B
Mol Med Rep; 2015 Nov; 12(5):7344-50. PubMed ID: 26459017
[TBL] [Abstract][Full Text] [Related]
24. Modulation of Inflammation-Related Genes in the Cornea of a Mouse Model of Dry Eye upon Treatment with Cyclosporine Eye Drops.
Daull P; Barabino S; Feraille L; Kessal K; Docquier M; Parsadaniantz SM; Baudouin C; Garrigue JS
Curr Eye Res; 2019 May; 44(5):476-485. PubMed ID: 30664361
[TBL] [Abstract][Full Text] [Related]
25. Effects of a new lipid tear substitute in a mouse model of dry eye.
Scifo C; Barabino S; De Pasquale G; Blanco AR; Mazzone MG; Rolando M
Cornea; 2010 Jul; 29(7):802-6. PubMed ID: 20489574
[TBL] [Abstract][Full Text] [Related]
26. Lacrimal gland inflammatory cytokine gene expression in the botulinum toxin B-induced murine dry eye model.
Park CY; Zhuang W; Lekhanont K; Zhang C; Cano M; Lee WS; Gehlbach PL; Chuck RS
Mol Vis; 2007 Nov; 13():2222-32. PubMed ID: 18087241
[TBL] [Abstract][Full Text] [Related]
27. Comparison of Topical Application of TSG-6, Cyclosporine, and Prednisolone for Treating Dry Eye.
Kim YJ; Ryu JS; Park SY; Lee HJ; Ko JH; Kim MK; Wee WR; Oh JY
Cornea; 2016 Apr; 35(4):536-42. PubMed ID: 26807900
[TBL] [Abstract][Full Text] [Related]
28. Mechanism for carbachol-induced secretion of lacritin in cultured monkey lacrimal acinar cells.
Morimoto-Tochigi A; Walkup RD; Nakajima E; Shearer TR; Azuma M
Invest Ophthalmol Vis Sci; 2010 Sep; 51(9):4395-406. PubMed ID: 20375347
[TBL] [Abstract][Full Text] [Related]
29. Clinical efficacy of combined topical 0.05% cyclosporine A and 0.1% sodium hyaluronate in the dry eyes with meibomian gland dysfunction.
Kim HY; Lee JE; Oh HN; Song JW; Han SY; Lee JS
Int J Ophthalmol; 2018; 11(4):593-600. PubMed ID: 29675376
[TBL] [Abstract][Full Text] [Related]
30. The Effect of the Aqueous Extract of Bidens Pilosa L. on Androgen Deficiency Dry Eye in Rats.
Zhang C; Li K; Yang Z; Wang Y; Si H
Cell Physiol Biochem; 2016; 39(1):266-77. PubMed ID: 27337217
[TBL] [Abstract][Full Text] [Related]
31. Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines.
Choi MG; Yeo JH; Kang JW; Chun YS; Lee JK; Kim JC
Graefes Arch Clin Exp Ophthalmol; 2019 Feb; 257(2):331-338. PubMed ID: 30552510
[TBL] [Abstract][Full Text] [Related]
32. A study of refractory cases of persistent epithelial defects associated with dry eye syndrome and recurrent corneal erosions successfully treated with cyclosporine A 0.05% eye drops.
Napoli PE; Braghiroli M; Iovino C; Demarinis G; Fossarello M
Drug Des Devel Ther; 2019; 13():2001-2008. PubMed ID: 31354245
[No Abstract] [Full Text] [Related]
33. Effect of 0.025% FK-506 eyedrops on botulinum toxin B-induced mouse dry eye.
Lin BW; Chen MZ; Fan SX; Chuck RS; Zhou SY
Invest Ophthalmol Vis Sci; 2014 Dec; 56(1):45-53. PubMed ID: 25491293
[TBL] [Abstract][Full Text] [Related]
34. Effects of topical anti-inflammatory agents in a botulinum toxin B-induced mouse model of keratoconjunctivitis sicca.
Lekhanont K; Park CY; Smith JA; Combs JC; Preechawat P; Suwan-Apichon O; Rangsin R; Chuck RS
J Ocul Pharmacol Ther; 2007 Feb; 23(1):27-34. PubMed ID: 17341147
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Efficacy Comparison of Cyclosporine Ophthalmic Solution 0.09% vs Cyclosporine Ophthalmic Emulsion 0.05% vs Ciclosporin Ophthalmic Emulsion 0.1% in a NOD Mouse Model of Dry Eye Disease.
Burade V; Zalawadia R; Patel A; Ogundele A
Clin Ophthalmol; 2020; 14():2747-2755. PubMed ID: 33061257
[TBL] [Abstract][Full Text] [Related]
36. Topical cyclosporine inhibits conjunctival epithelial apoptosis in experimental murine keratoconjunctivitis sicca.
Strong B; Farley W; Stern ME; Pflugfelder SC
Cornea; 2005 Jan; 24(1):80-5. PubMed ID: 15604871
[TBL] [Abstract][Full Text] [Related]
37. Investigation of capsaicin-induced superficial punctate keratopathy model due to reduced tear secretion in rats.
Kagawa Y; Itoh S; Shinohara H
Curr Eye Res; 2013 Jul; 38(7):729-35. PubMed ID: 23557342
[TBL] [Abstract][Full Text] [Related]
38. Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial.
Park DH; Chung JK; Seo DR; Lee SJ
Am J Ophthalmol; 2016 Mar; 163():122-131.e2. PubMed ID: 26685791
[TBL] [Abstract][Full Text] [Related]
39. Establishment of an appropriate animal model for lacritin studies: cloning and characterization of lacritin in monkey eyes.
Nakajima T; Walkup RD; Tochigi A; Shearer TR; Azuma M
Exp Eye Res; 2007 Nov; 85(5):651-8. PubMed ID: 17850790
[TBL] [Abstract][Full Text] [Related]
40. Short-Term Effects of Ground-Level Ozone in Patients With Dry Eye Disease: A Prospective Clinical Study.
Kim Y; Paik HJ; Kim MK; Choi YH; Kim DH
Cornea; 2019 Dec; 38(12):1483-1488. PubMed ID: 31299662
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
